ストックスクリーナーアプリを入手
2.56
1.19%
0.03
プレマーケット:
2.55
-0.01
-0.39%
前日終値:
$2.53
開ける：
$2.51
24時間の取引高:
232.79K
Relative Volume:
0.63
時価総額：
$18.69M
収益：
$1.98M
当期純損益:
$-9.63M
株価収益率:
-1.4502
EPS:
-1.7653
ネットキャッシュフロー:
$-9.76M
1週間 パフォーマンス:
+20.19%
1か月 パフォーマンス:
-65.12%
6か月 パフォーマンス:
-17.69%
1年 パフォーマンス:
-16.07%
1日の値動き範囲:
$2.48
$2.63
1週間の範囲:
$2.01
$2.63
52週間の値動き範囲:
$1.81
$12.37
Lipocine Inc Stock (LPCN) Company Profile
名前
Lipocine Inc
セクター
電話
801 994 7383
住所
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
2.56 | 18.69M | 1.98M | -9.63M | -9.76M | -1.7653 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 112.35B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.71B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 52.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 44.48B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 35.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-06-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-01-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2015-07-22 | 開始されました | ROTH Capital | Buy |
| 2015-06-23 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Lipocine Inc (LPCN) 最新ニュース
LPCN stock crashes 78%—here’s why - MSN
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Quarterly Risk: What is the Moat Score of Lipocine IncMarket Growth Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
What's going on with Lipocine stock on Monday? - MSN
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 - Investing.com UK
Higuchi John W. buys Lipocine (LPCN) shares worth $81199 By Investing.com - Investing.com India
Director John Higuchi adds 40,000 Lipocine (LPCN) shares at $2.03 - Stock Titan
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock - Defense World
CEO Mahesh Patel Increases Stake in Lipocine Inc with Recent Sha - GuruFocus
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 By Investing.com - Investing.com Australia
Higuchi John W. buys Lipocine (LPCN) shares worth $252,149 - Investing.com
Director John W. Higuchi buys 123K Lipocine (LPCN) shares at $2.05 - Stock Titan
Lipocine CEO Patel acquires $50,749 in LPCN stock - Investing.com UK
Lipocine CEO Patel acquires $50,749 in LPCN stock By Investing.com - Investing.com India
Lipocine (LPCN) CEO adds 25,000 shares in stock purchase - Stock Titan
Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED - biocentury.com
LPCN Downgraded to Neutral by HC Wainwright & Co. | LPCN Stock N - GuruFocus
What's Going On With Lipocine Stock On Monday? - Benzinga
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
H.C. Wainwright Downgrades Lipocine(LPCN.US) to Hold Rating - Moomoo
Lipocine Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
Lipocine’s Phase 3 Trial Failure Triggers Stock Drop, Strategic Reevaluation - timothysykes.com
Lipocine Faces Market Setback as LPCN 1154 Fails Key Trial - StocksToTrade
LPCN Should I Buy - Intellectia AI
Lipocine Stock Plummets After Clinical Trial Disappointment - StocksToTrade
Lipocine Updates Investor Presentation to Refine Market Messaging - The Globe and Mail
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint - Sahm
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results - Sahm
Nasdaq Down 1%; US Initial Jobless Claims Fall - Sahm
Lipocine Inc (ticker: LPCN) announced that its experimental drug for postpartum depression failed to meet the primary endpoint in its Phase III clinical trial, causing the company's stock price to plummet by 78.4% in pre-market trading. - Bitget
Lipocine Tumbles 78.6% Intraday: Is This A Volatility Shock or a Reckoning? - Bitget
LPCN | Lipocine Inc. Insider Trading - Quiver Quantitative
CEO Mahesh Patel Acquires 25,000 Shares of Lipocine Inc (LPCN) - GuruFocus
Lipocine CEO buys 25,000 shares in open market | LPCN Insider Trading - Stock Titan
Oral ‘roid void in PPD? Lipocine MINI bike may have wheels - BioWorld MedTech
LPCN Stock Crashes 78%— Here’s Why - Stocktwits
Lipocine weighs path after LPCN 1154 Phase 3 miss - TipRanks
Lipocine Reports Topline Safety and Efficacy Results for LPCN 11 - GuruFocus
[8-K] Lipocine Inc. Reports Material Event - Stock Titan
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Lipocine stock tumbles after phase 3 trial misses endpoint By Investing.com - Investing.com Australia
Lipocine stock tumbles after phase 3 trial misses endpoint - Investing.com
Lipocine's postpartum depression pill misses main goal in late-stage study - TradingView — Track All Markets
Lipocine Inc (LPCN) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):